Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Formulations Based on Natural Ingredients for the Treatment of Nail Diseases

Author(s): Silvia Tampucci, Eleonora Terreni, Erica Zucchetti, Susi Burgalassi, Patrizia Chetoni and Daniela Monti*

Volume 26, Issue 5, 2020

Page: [556 - 565] Pages: 10

DOI: 10.2174/1381612826666200122150248

Price: $65

Abstract

Nail is a strong and resistant structure, characterized by a low permeability to foreign molecules. Nails can be subjected to many diseases, among which fungal infections (e.g. onchomycosis) are the most common and responsible for nail structure alteration. Many formulations have been produced for the delivery of active ingredients to treat nail disorders, based on newly synthesized active molecules or containing chemical enhancers or chemically-modified polymers able to improve the drug transungual penetration. To avoid permanent alterations of the nail structure due to the use of chemical compounds or organic solvent-based formulation, researchers have developed novel formulations focusing on the use of new natural-based compounds. The purpose of this review is to provide information on the outcoming of natural ingredients-based formulations that have been developed in the last years as potential alternative to chemical-based formulations.

Keywords: Natural compounds, nail diseases, natural polymers, natural enhancers, nail formulations, onchomycosis.

« Previous Next »
[1]
Shanbhag PP, Jani U. Drug delivery through nails: present and future. New Horiz Transl Med 2017; 3: 252-63.
[2]
de Berker D. Nail anatomy. Clin Dermatol 2013; 31(5): 509-15.
[http://dx.doi.org/10.1016/j.clindermatol.2013.06.006] [PMID: 24079579 ]
[3]
Dhamoon RK, Popli H, Gupta M. Novel drug delivery strategies for the treatment of onychomycosis. Pharm Nanotechnol 2019; 7(1): 24-38.
[http://dx.doi.org/10.2174/2211738507666190228104031] [PMID: 31092174 ]
[4]
Monti D, Saccomani L, Chetoni P, Burgalassi S, Saettone MF, Mailland F. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm 2005; 31(1): 11-7.
[http://dx.doi.org/10.1081/DDC-43935] [PMID: 15704853 ]
[5]
Akhtar N, Sharma H, Pathak K. Onychomycosis: potential of nail lacquers in transungual delivery of antifungals. Scientifica (Cairo) 2016; 2016 1387936
[http://dx.doi.org/10.1155/2016/1387936] [PMID: 27123362 ]
[6]
Baswan S, Kasting GB, Li SK, et al. Understanding the formidable nail barrier: a review of the nail microstructure, composition and diseases. Mycoses 2017; 60(5): 284-95.
[http://dx.doi.org/10.1111/myc.12592] [PMID: 28098391 ]
[7]
Maddy AJ, Tosti A. What’s new in nail disorders. Dermatol Clin 2019; 37(2): 143-7.
[http://dx.doi.org/10.1016/j.det.2018.12.004] [PMID: 30850036 ]
[8]
Pasch MC. Nail Psoriasis: a Review of treatment options. Drugs 2016; 76(6): 675-705.
[http://dx.doi.org/10.1007/s40265-016-0564-5] [PMID: 27041288 ]
[9]
Piraccini BM, Starace M. Optimal management of nail disease in patients with psoriasis Psoriasis. Auckl 2015; 5: 25.
[10]
Christi JM, Aundhia C, Seth A, Shah N, Kondhia D, Patel S. Review on transungual drug delivery system. IAJPR 2017; 7: 686-706.
[11]
Kushwaha AS. The screening of permeation enhancers for trans-nail delivery of terbinafine hydrocloride. J Bioequivalence Bioavailab 2018; 10: 75-7.
[http://dx.doi.org/10.4172/0975-0851.1000381]
[12]
Palekar Shanbhag P, Jani U. Drug delivery through nails: present and future. European J Mol Clin Med 2017; 3(5): 252-63.
[http://dx.doi.org/10.1016/j.nhtm.2017.01.002]
[13]
Liddell LT, Rosen T. Laser Therapy for Onychomycosis: Fact or Fiction? J Fungi (Basel) 2015; 1(1): 44-54.
[http://dx.doi.org/10.3390/jof1010044] [PMID: 29376898 ]
[14]
Angelo T, Borgheti-Cardoso LN, Gelfuso GM, Taveira SF, Gratieri T. Chemical and physical strategies in onychomycosis topical treatment: A review. Med Mycol 2017; 55(5): 461-75.
[PMID: 27703019 ]
[15]
Kline-Schoder A, Le Z, Zderic V. Ultrasound-enhanced drug delivery for treatment of onychomycosis. J Ultrasound Med 2018; 37(7): 1743-52.
[http://dx.doi.org/10.1002/jum.14526] [PMID: 29288596 ]
[16]
Asri M, Ramli S. Study on the effect of oil phase and co-surfactant on microemulsion systems. Malays J Anal Sci 2018; 21(6): 1409-16.
[17]
Xavier-Junior FH, Vauthier C, Morais ARV, Alencar EN, Egito EST. Microemulsion systems containing bioactive natural oils: an overview on the state of the art. Drug Dev Ind Pharm 2017; 43(5): 700-14.
[http://dx.doi.org/10.1080/03639045.2016.1235186] [PMID: 27622950 ]
[18]
Bseiso EA, Nasr M, Sammour OA, Abd El Gawad NA. Novel nail penetration enhancer containing vesicles “nPEVs” for treatment of onychomycosis. Drug Deliv 2016; 23(8): 2813-9.
[http://dx.doi.org/10.3109/10717544.2015.1099059] [PMID: 26447337 ]
[19]
Lipner SR. Pharmacotherapy for onychomycosis: new and emerging treatments. Expert Opin Pharmacother 2019; 20(6): 725-35.
[http://dx.doi.org/10.1080/14656566.2019.1571039] [PMID: 30689469 ]
[20]
Tabara K, Szewczyk AE, Bienias W, et al. Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis. Postepy Dermatol Alergol 2015; 32(1): 40-5.
[http://dx.doi.org/10.5114/pdia.2014.40968] [PMID: 25821426 ]
[21]
McAuley WJ, Jones SA, Traynor MJ, Guesné S, Murdan S, Brown MB. An investigation of how fungal infection influences drug penetration through onychomycosis patient’s nail plates. Eur J Pharm Biopharm 2016; 102: 178-84.
[http://dx.doi.org/10.1016/j.ejpb.2016.03.008] [PMID: 26969264 ]
[22]
Monti D, Tampucci S, Chetoni P, Burgalassi S, Mailland F. Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers. J Drugs Dermatol 2014; 13(2): 143-7.
[PMID: 24509963 ]
[23]
Jublia FDA. 2014 Available at:.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf
[24]
Sugiura K, Sugimoto N, Hosaka S, et al. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment. Antimicrob Agents Chemother 2014; 58(7): 3837-42.
[http://dx.doi.org/10.1128/AAC.00111-14] [PMID: 24752277 ]
[25]
Tampucci S, Terreni E, Burgalassi S, Chetoni P, Monti D. Development and validation of an HPLC-UV method to quantify tavaborole during in vitro transungual permeation studies. J AOAC Int 2018; 101(2): 437-43.
[http://dx.doi.org/10.5740/jaoacint.17-0039] [PMID: 28766480 ]
[26]
Kubota-ishida N, Takei-masuda N, Kaneda K, Nagira Y, Chikada T, Nomoto M. In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis. Antimicrob Agents Chemother 2017; 62(1)
[PMID: 29084749 ]
[27]
El-sherif NI, Shamma RN, Abdelbary G. In-situ gels and nail lacquers as potential delivery systems for treatment of onychomycosis. A comparative study. Drug Deliv Sci and Technol 2018; 43: 253-61.
[http://dx.doi.org/10.1016/j.jddst.2017.10.018]
[28]
Gómez EC, Anguiano Igea S, Gómez Amoza JL, Otero Espinar FJ. Evaluation of the promoting effect of soluble cyclodextrins in drug nail penetration. Eur J Pharm Sci 2018; 117: 270-8.
[http://dx.doi.org/10.1016/j.ejps.2018.02.028] [PMID: 29501459 ]
[29]
Monti D, Saccomani L, Chetoni P, Burgalassi S, Tampucci S, Mailland F. Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation. Br J Dermatol 2011; 165(1): 99-105.
[http://dx.doi.org/10.1111/j.1365-2133.2011.10303.x] [PMID: 21410668 ]
[30]
Monti D, Egiziano E, Burgalassi S, et al. Influence of a combination of chemical enhancers and iontophoresis on in vitro transungual permeation of nystatin. AAPS PharmSciTech 2018; 19(4): 1574-81.
[http://dx.doi.org/10.1208/s12249-018-0977-4] [PMID: 29484614 ]
[31]
Bardazzi F, Starace M, Bruni F, Magnano M, Piraccini BM, Alessandrini A. Nail psoriasis: an updated review and expert opinion on available treatments, including biologics. Acta Derm Venereol 2019; 99(6): 516-23.
[http://dx.doi.org/10.2340/00015555-3098] [PMID: 30521057 ]
[32]
Mailland F, Caserini M, Ceriani D. inventors; Federico Mailland- Michela LegoraDaniela CerianiGiuliana Iob, assignee. Method to treat onychomicosys by hydroxypropyl chitosan. Unoted States patent PCT/EP2014/069099, US 2016/0213705 A1 2013.
[33]
Monti D, Saccomani L, Chetoni P, et al. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity. Br J Dermatol 2010; 162(2): 311-7.
[http://dx.doi.org/10.1111/j.1365-2133.2009.09504.x] [PMID: 19886884 ]
[34]
Dubini F, Bellotti MG, Frangi A, Monti D, Saccomani L. In vitro antimycotic activity and nail permeation models of a piroctone olamine (octopirox) containing transungual water soluble technology. Arzneimittelforschung 2005; 55(8): 478-83.
[PMID: 16149717 ]
[35]
Ghannoum M, Long L, Kunze G, Sarkany M, Osman-Ponchet H. A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails. Mycoses 2019; 62(6): 494-501.
[http://dx.doi.org/10.1111/myc.12896] [PMID: 30667544 ]
[36]
Çelebi N, Ermiş S, Özkan S. Development of topical hydrogels of terbinafine hydrochloride and evaluation of their antifungal activity. Drug Dev Ind Pharm 2015; 41(4): 631-9.
[http://dx.doi.org/10.3109/03639045.2014.891129] [PMID: 24576265 ]
[37]
Flores FC, Rosso RS, Cruz L, Beck RCR, Silva CB. An innovative polysaccharide nanobased nail formulation for improvement of onychomycosis treatment. Eur J Pharm Sci 2017; 100: 56-63.
[http://dx.doi.org/10.1016/j.ejps.2016.12.043] [PMID: 28063967 ]
[38]
Tanrıverdi ST, Hilmioğlu Polat S, Yeşim Metin D, Kandiloğlu G, Özer Ö. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: in vitro and in vivo evaluation. J Liposome Res 2016; 26(2): 163-73.
[http://dx.doi.org/10.3109/08982104.2015.1067892] [PMID: 26226352 ]
[39]
Khattab A, Shalaby S. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of endopeptidase enzyme as permeation enhancer on transungual drug delivery and efficiency against onychomycosis. AAPS PharmSciTech 2018; 19(3): 1048-60.
[http://dx.doi.org/10.1208/s12249-017-0917-8] [PMID: 29138987 ]
[40]
Hafeez F, Hui X, Selner M, Rosenthal B, Maibach H. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers. Drug Dev Ind Pharm 2014; 40(6): 838-44.
[http://dx.doi.org/10.3109/03639045.2013.788016] [PMID: 23600655 ]
[41]
Singh V, Gupta RD, Correspondence F. Investigation of novel penetration enhancer lawsonia inermis for drug delivery through nail plate. J Pharm App Sci 2014; 2: 34-8.
[42]
Singh V, Chandrul KK. Inspection of novel penetration enhancer for transungual drug delivery system: pelargonium hortorum. J Pharm App Sci 2015; 3: 22-5.
[43]
Singh V, Chandrul KK. Formulation and evaluation the transungual drug delivery system of fluconazole with penetration enhancers: Iresine Herbestii. Indo Am J Pharm Res 2016; 3: 377-87.
[44]
Veiga FF, Gadelha MC, da Silva MRT, et al. Propolis extract for onychomycosis topical treatment: from bench to clinic. Front Microbiol 2018; 9: 779.
[http://dx.doi.org/10.3389/fmicb.2018.00779] [PMID: 29922236 ]
[45]
Khosravi AR, Shokri H, Nikaein D, et al. Yeasts as important agents of onychomycosis: in vitro activity of propolis against yeasts isolated from patients with nail infection. J Altern Complement Med 2013; 19(1): 57-62.
[http://dx.doi.org/10.1089/acm.2011.0722] [PMID: 22954465 ]
[46]
Robles-Martínez M, González J F C, Pérez-Vázquez F J, Montejano-Carrizales J M, Pérez E, Patiño-Herrera R C B. 2019 16: e1800525.
[47]
da Silva AP, Carbinato FM, Bagnato SV, Inada MN. A promising strategy for the treatment of onychomycosis with curcumin and photodynamic therapy. J Pharm Pharmacol 2015; 3: 434-7.
[http://dx.doi.org/10.17265/2328-2150/2015.09.005]
[48]
Tirant M, Hercogovấ J, Fioranelli M, et al. Nail psoriasis in an adult successfully treated with a series of herbal skin care products family: a case report. J Bio regul Homeost Agents 2016; 30: 21-8.
[49]
Sparavigna A, Tenconi B, La Penna L. Efficacy and tolerability of a biomineral formulation for treatment of onychoschizia: a randomized trial. Clin Cosmet Investig Dermatol 2019; 12: 355-62.
[http://dx.doi.org/10.2147/CCID.S187305] [PMID: 31190943 ]
[50]
Pereira RR, Testi M, Rossi F, et al. Ucuùba (virola surinamensis) fat-based nanostructured lipid carriers for nail drug delivery of ketoconazole: development and optimization using box-behnken design. Pharmaceutics 2019; 11(6): 284.
[http://dx.doi.org/10.3390/pharmaceutics11060284] [PMID: 31212993 ]
[51]
Shah VH, Jobanputra A. Enhanced ungual permeation of terbinafine HCl delivered through liposome-loaded nail lacquer formulation optimized by QbD approach. AAPS PharmSciTech 2018; 19(1): 213-24.
[http://dx.doi.org/10.1208/s12249-017-0831-0] [PMID: 28681334 ]
[52]
Tiwari S, Mistry P, Patel V. SLNs based on co-processed lipids for topical delivery of terbinafine hydrochloride. J Pharmaceut Drug Develop 2014; 2(14): 1-8.
[53]
Fernandez Gonzalez A, Fernandez Leon M. Method for preparing products made on leaves of the sedum telephium plant for the treatment of nail infected with onychomychosis. United States patent US 2019/0167744A1 2019 June.
[54]
Fernandez Gonzalez A, Fernandez Leon M. Method for preparing products made on leaves of the sedum telephium plant for the treatment of nail infected with onychomychosis. United States patent US 2018/0028586A1 2018 Feb.
[55]
Taft CA. inventor. Topical composition for treatment of skin, hair, and/or nails and method of using the same. United States patent US 009668965B2 2017 June.
[56]
Taft CA. inventor. Topical composition for treatment of skin, hair, and/or nails and method of using the same. United States patent US 009446082B2 2016 Sep.
[57]
Chamberland G, Lee W. inventors. Herbal composition and methods for the prevention and treatment of plant of nail infection. United States patent US 2019/0038696A1 2019 Feb.

Rights & Permissions Print Cite
Article Metrics
19
2
© 2024 Bentham Science Publishers | Privacy Policy